anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Defects in the low-density lipoprotein receptor (LDLR) are associated with familial hypercholesterolemia (FH), manifested by atherosclerosis and cardiovascular disease. LDLR deficiency in hepatocytes leads to elevated blood cholesterol levels, which damage vascular cells, especially endothelial cells, through oxidative stress and inflammation. However, the distinctions between endothelial cells from individuals with normal and defective LDLR are not yet fully understood. In this study, we obtained and examined endothelial derivatives of induced pluripotent stem cells (iPSCs) generated previously from conditionally healthy donors and compound heterozygous FH patients carrying pathogenic LDLR alleles. In normal iPSC-derived endothelial cells (iPSC-ECs), we detected the LDLR protein predominantly in its mature form, whereas iPSC-ECs from FH patients have reduced levels of mature LDLR and show abolished low-density lipoprotein uptake. RNA-seq of mutant LDLR iPSC-ECs revealed a unique transcriptome profile with downregulated genes related to monocarboxylic acid transport, exocytosis, and cell adhesion, whereas upregulated signaling pathways were involved in cell secretion and leukocyte activation. Overall, these findings suggest that LDLR defects increase the susceptibility of endothelial cells to inflammation and oxidative stress. In combination with elevated extrinsic cholesterol levels, this may result in accelerated endothelial dysfunction, contributing to early progression of atherosclerosis and other cardiovascular pathologies associated with FH.
The invention provides an antibiotic and anti-ageing cosmetic. The cosmetic contains a Folium Eucommiae extract chlorogenic acid and Ginkgo flavone aglycone, the Folium Eucommiae extract chlorogenic acid is obtained by decocting Folium Eucommiae in water, and the Ginkgo flavone aglycone is obtained by extracting and purifying through a physical method, and the Folium Eucommiae extract chlorogenic acid has a wide antibiotic effect, and can be inactivated by proteins in vivo. The cosmetic becomes non-allergenic substances through the effect of small intestinal secretions after the cosmetic is eaten. The cosmetic has bleeding stopping, leukocyte raising and virus preventing effects, and also has blood clotting and hemorrhage time shortening effects. The Ginkgo flavone aglycone has a small molecular weight, can be rapidly absorbed by human bodies, can pass through the blood brain barrier, and can enter cell tissues, so the Ginkgo flavone aglycone has the functions of fatigue elimination, blood vessel protection, capillary vessel expansion, microcirculation dredging, fat oxidation resistance and ageing resistance. Therefore, the cosmetic is harmless to the human bodies, and is benefit for the health of the bodies.
Consecutive patients with GIM under endoscopic surveillance or examination at Qilu Hospital from March 1 to September 31, 2015 were recruited into this study. Before the endomicroscopic examination, 20,000 U α-chymotrypsin and 80 mg dimethylpolysiloxane were given orally to remove gastric mucus. All patients were given intravenous injections of 1 ml of 2% fluorescein sodium (Baiyunshan Mingxing Pharmaceutical, Guangzhou, China) as an allergy test before procedures were carried out. Conscious sedation was achieved for each patient by using propofol and fentanyl, and vital signs were monitored during the entire procedure. After successful intubation of the endoscope into the gastric antrum, 1 mL fluorescein sodium solution was applied intravenously as a contrast dye. The CLE procedure did not differ from that of conventional colonoscopy, except for the additional storage of pCLE images and videos in the gastric antrum. Finally, targeted biopsy of the examined site was performed.
Provides a set of adenovirus vector system and recombinant virus construction method. The vector system comprises adenovirus plasmids pKAD5f11p-EF1aP, pKAD5f11pES-PmeI and shuttle plasmid pUC 19-PM. The adenovirus plasmid contains E1/E3 deletion human adenovirus type 5 HAdV-5 genome, and the original HAdV-5fiber is replaced by HAdV-5 and HAdV-11p fusion gene F5-11 p; the PmeI site is an exogenous gene insertion site. pKAD5f11p-EF1aP contains the human EF1a promoter. The shuttle plasmid pUC19-PM can be used with pKAD5f11 pES-PmeI. The construction method comprises the following steps: carrying out PCR amplification on target genes containing homologous overlapping regions on two sides, and carrying out DNA assembly on the target genes and adenovirus plasmids linearized by PmeI to obtain adenovirus plasmids containing the target genes; or cloning the exogenous gene fragment into a shuttle plasmid, cutting the shuttle plasmid by endonuclease, and then carrying out DNA assembly with PmeI linearized pKAD5f11 pES-PmeI. The invention combines restriction enzyme cutting and DNA assembling technology, and fully simplifies the adenovirus vector construction process.
BACKGROUND: Chronic/latent viral infections may accelerate immunological aging, particularly among people living with HIV (PLWH). We characterized chronic/latent virus infections across their lifespan and investigated their associations with leukocyte telomere length (LTL).
METHODS: Participants enrolled in the CARMA cohort study were randomly selected to include n = 15 for each decade of age between 0 and >60 y, for each sex, and each HIV status. Cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus 8 (HHV-8), herpes simplex virus 1 (HSV-1), and HSV-2 infection were determined serologically; HIV, hepatitis C (HCV), and hepatitis B (HBV) were self-reported. LTLs were measured using monochrome multiplex qPCR. Associations between the number of viruses, LTL, and sociodemographic factors were assessed using ordinal logistic and linear regression modeling.
RESULTS: The study included 187 PLWH (105 female/82 male) and 190 HIV-negative participants (105 female/84 male), ranging in age from 0.7 to 76.1 years. Living with HIV, being older, and being female were associated with harbouring a greater number of chronic/latent non-HIV viruses. Having more infections was in turn bivariately associated with a shorter LTL. In multivariable analyses, older age, living with HIV, and the female sex remained independently associated with having more infections, while having 3-4 viruses (vs. 0-2) was associated with a shorter LTL.
CONCLUSIONS: Our results suggest that persistent viral infections are more prevalent in PLWH and females, and that these may contribute to immunological aging. Whether this is associated with comorbidities later in life remains an important question.
Techniques for unbounded therapy evaluation are provided. A request to suggest a potential therapy based on a patient profile is received. A plurality of accepted therapies is determined based on the patient profile, where the plurality of accepted therapies is based on stored definitions obtained from one or more subject matter experts. Next, a plurality of therapy components is identified based on the plurality of accepted therapies. A plurality of potential therapies is then identified based on the plurality of therapy components, where none of the plurality of potential therapies are included in the plurality of accepted therapies. A score is generated for a potential therapy of the plurality of potential therapies based on analyzing a knowledge graph, where the score indicates a suitability of the potential therapy for a patient associated with the patient profile. Finally, the potential therapy is provided, along with an indication of the score.
The invention discloses a Zhuang medicine composition for treating benign prostatic hyperplasia. The Zhuang medicine composition comprises the following raw materials in parts by weight: 30-80 parts of panicled fameflower root, 10-30 parts of root of false-yellowflower milkwort, 10-30 parts of twelve stamen melastoma herb, 10-40 parts of root of sarmentose pepper, 10-40 parts of leaf of leatherleaf mahonia, 30-50 parts of twotooth achyranthes root, 20-30 parts of largehead atractylodes rhizome, 10-30 parts of cassia twig, 10-30 parts of cattail pollen, 5-30 parts of seaweed, 10-20 parts of kelp and 5-20 parts of licorice root. The preparation method of the Zhuang medicine composition comprises the following steps: weighing the raw materials according to the weight parts respectively, cleaning and screening decoction piece medicinal materials of the composition, adding water, decocting with slow fire until the volume is 200ml, and re-decocting herb residues, thereby obtaining a mixture in the form of decoction for storage. The dosage form is decoction. The Zhuang medicine composition disclosed by the invention has the effects of reinforcing kidney to nourish qi and promoting diuresis. The Zhuang medicine composition replenishes qi and blood respectively according to deficiencies of qi, blood, yin and yang; and on the other hand, the composition removes water moisture retention by virtue of replenishment, can strengthen the middle warmer as well as remove the water moisture retention, and can treat both symptoms and root causes, so that the composition is an effective medicine for treating the benign prostatic hyperplasia.
Participants will receive GDC-1971 orally at the assigned dose QD on Days 1-21 of each cycle and atezolizumab 1200 mg IV on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit. A subset of participants will participate in evaluations regarding tablet vs capsule formulation, the effect of food and acid-reducing agents on GDC-1971.
Check blood gas before induction without preoxygen. Take stomach-ultrasound. Induction with Midazolam 0.02 mg/kg, sufentanil 0.3 \~ 0.5 ug/kg, propofol 2-2.5 mg/kg, rocuronium 0.6 mg/kg.After patients fall asleep and can't be woke up ,the investigators will put the Wei NASAL JET（WNJ）into one's nose to give the supraglottic jet ventilation with the driving pressure 0.01-0.03 megapascal (MPa), respiratory rate 15 beats per minute（BPM）, inspiratory/expiratory rate 1-1. 5.Check blood gas,stomach-ultrasound after 3 min, then do the tracheal intubation guided by visual laryngoscope.Stop jet ventilation during intubation.
Participants receive MK-8189 (4 mg controlled release \[CR\] oral tablet\[s\]) in combination with placebo matching risperidone (oral capsule\[s\]) once daily (QD) for 4 weeks. Over the initial 7 treatment days, MK-8189 is titrated from 4 mg to 12 mg as follows: 4 mg (1 tablet; Day 1); 8 mg (2 tablets; Day 4); and 12 mg (3 tablets; Day 7). Placebo matching risperidone is also titrated as follows: 1 capsule (Day 1), 2 capsules (Day 4), and 3 capsules (Day 7). After Day 7, MK-8189 is maintained at 12 mg (3 tablets) in combination with placebo matching risperidone (3 capsules), QD for 3 weeks.
BACKGROUND: The territory of D3-D4 lymphadenectomy for upper rectal and sigmoid colon cancer varies, and its oncological efficacy is unclear. This prospective study aimed to standardize the surgical technique of robotic D3-D4 lymphadenectomy and clarify its oncologic significance.
METHODS: Patients with upper rectal or sigmoid colon cancer with clinically suspected more than N2 lymph node metastasis were prospectively recruited to undergo standardized robotic D3-D4 lymphadenectomy. Immediately postsurgery, the retrieved lymph nodes were mapped to five N3-N4 nodal stations: the inferior mesenteric artery, para-aorta, inferior vena cava, infra-renal vein, and common iliac vessels. Patients were stratified according to their nodal metastasis status to compare their clinicopathological data and overall survival. Univariate and multivariate analyses were performed to determine the relative prognostic significance of the five specific nodal stations. Surgical outcomes and functional recovery of the patients were assessed using the appropriate variables.
RESULTS: A total of 104 patients who successfully completed the treatment protocol were assessed. The standardized D3-D4 lymph node dissection harvested sufficient lymph nodes (34.4±7.2) for a precise pathologic staging. Based on histopathological analysis, 28 patients were included in the N3-N4 nodal metastasis-negative group and 33, 34, and nine patients in the single-station, double-station, and triple-station nodal metastasis-positive groups, respectively. Survival analysis indicated no significant difference between the single-station nodal metastasis-positive and N3-N4 nodal metastasis-negative groups in the estimated 5-year survival rate [53.6% (95% CI: 0.3353-0.7000) vs. 71.18% (95% CI: 0.4863-0.8518), P=0.563], whereas patients with double-station or triple-station nodal metastatic disease had poor 5-year survival rates (24.76 and 22.22%), which were comparable to those of AJCC/UICC stage IV disease than those with single-station metastasis-positive disease. Univariate analysis showed that the metastatic status of the five nodal stations was comparable in predicting the overall survival; in contrast, multivariate analysis indicated that common iliac vessels and infra-renal vein were the only two statistically significant predictors (P<0.05) for overall survival.
CONCLUSIONS: Using a robotic approach, D3-D4 lymph node dissection could be safely performed in a standardized manner to remove the relevant N3-N4 lymphatic basin en bloc, thereby providing significant survival benefits and precise pathological staging for patients. This study encourages further international prospective clinical trials to provide more solid evidence that would facilitate the optimization of surgery and revision of the current treatment guidelines for such a clinical conundrum.
PURPOSE:To provide the titled plaster having a drug-impermeable substrate supporting a pressure-sensitive adhesive layer containing a drug at an amount above its saturation solubility, applicable by heating before use to convert the drug to a supersaturated dissolved state, giving high drug concentration in blood and capable of keeping the concentration over a long period. CONSTITUTION:A surface of a drug-impermeable substrate is coated with a pressure-sensitive adhesive layer containing a drug at an amount above its saturation solubility (>=1.2 times, especially 1.5-3 times the solubility) and keeping the drug in a supersaturated dissolved state. The drug is solid at <=30 deg.C. If necessary, an absorbefacient is added to the pressure-sensitive adhesive layer at an amount of <=30wt%. When the plaster is heated before use, the drug crystal precipitated in the pressure-sensitive adhesive layer during the long-term storage is redissolved to form a supersaturated dissolved state. The transcutaneous permeability and the initial releasability of the drug can be improved and the drug concentration in blood can be maintained at a high level.
1\. Remove cap from can. If this is the first time using can, break the protective shipping tab by gently lifting up the trigger.

2\. Shake can thoroughly for at least 10 seconds before each use.

3\. Completely invert can and slowly depress trigger to dispense foam into a fluoride tray

4\. Air dry teeth thoroughly and insert tray into patient’s mouth. Have patient close into the tray and use a slight chewing motion to ensure interproximal coverage.

5\. Leave tray in contact with teeth between 1-4 minutes. Use a saliva ejector during treatment to minimize ingestion of product

6\. Remove tray after elapsed time and have patient expectorate. Instruct patient to refrain from drinking, eating, or rinsing for 30 minutes after treatment.

Treatment frequency should not exceed 4 treatments per year.
The invention consists of a preparation for the oral administration of the probiotic shewanella pdp11 to fish. The preparation is characterized by containing viable bacterial cells of the strain cect 7627 encapsulated in a hydrogel based on calcium alginate in the form of spherical particles of uniform morphology and modifiable size to adapt to fish of different sizes. The capsules contain organoleptic and/or nutritional additives that act as attractants for the animals. The preparation keeps the bacteria viable for prolonged periods, is stable in aquatic environments, and supports passage through the digestive tract of fish, on which it exerts favorable biological effects. Its oral administration is independent of the usual food, thus preventing inactivation of the microorganism during the manufacture of the feed. (Machine-translation by Google Translate, not legally binding)
PCT No. PCT/EP98/00931 Sec. 371 Date Oct. 26, 1998 Sec. 102(e) Date Oct. 26, 1998 PCT Filed Feb. 18, 1998 PCT Pub. No. WO98/38255 PCT Pub. Date Sep. 3, 1998Multilayer interference pigment consisting of a central, absorbing layer and alternating layers of a material of low refractive index and of a metal or of a material of high refractive index either side of the central layer, the material of low refractive index preferably being acrylate and the metal being aluminium or chromium. The absorbing layer consists of a coating system which comprises carbon black or color-imparting absorption pigments.
The invention provides a preparation for treating cough, a preparation method and a quality control method thereof. The preparation is mainly a mixture which comprises the following raw materials in parts by weight: 8-12 parts of snake bile, 4-10 parts of fritillaria cirrhosa, 10-16 parts of exocarpium citrus grandis, 2-4 parts of mint, 10-16 parts of armeniaca amara, 36-40 parts of folium eriobotryae, 10-16 parts of radix platycodi, 16-22 parts of radix ophiopogonis, and 16-22 parts of radix glycyrrhizae. The preparation is prepared by using production processes including percolation, distillation, water extraction, and activated carbon adsorption, and is long in product storage life, less prone to denaturation, and strong in environment adaption. The preparation for treating cough, provided by the invention, is changed from the syrup to mixture, so as to improve the product quality standard and make the treatment effect better. The preparation method of the preparation for treating cough, provided by the invention, adopts the production processes including percolation, distillation, water extraction, and activated carbon adsorption, so as to enable the product to be long in storage life, less prone to denaturation, and strong in environment adaption. The quality control method of the preparation for treating cough, provided by the invention, can guarantee the content of each component of the product and ensure effective components of the medicine.
OBJECTIVES: Abdominal pain is a common presentation in patients of diabetic ketoacidosis (DKA). However, this pain generally resolves with resolution of dehydration and acidosis. Persistence of abdominal pain even after resolution of ketosis and acidosis should warrant careful reassessment to find evidence of sepsis and concomitant abdominal pathology.
CASE PRESENTATION: We report a rare case of type 1 diabetes mellitus in a 15 year old girl diagnosed 6 months ago who presented with mild DKA (pH 7.24, HCO3 - 13.5 mmol/L). Her hospital course was extremely stormy and despite best of our efforts she succumbed due to colonic ischemia and perforation peritonitis.
CONCLUSIONS: A high index of suspicion for gut ischemia or perforation should be kept if DKA is associated with septic shock and there is suboptimal response to standard treatment. Mesenteric ischemia can occur in pediatric patients even with mild DKA having very poor diabetes control.
This is a randomized, assessor-blinded study that involves the use of telerehabilitation to deliver additional therapy for persons with stroke. Patients with arm weakness due to stroke that happened in the past 90-150 days will be randomized into one of two groups: \[1\] TR and usual care; \[2\] usual care only (no TR), but people in the usual care group will be offered TR once the study is done. TR consists of 70 minutes/day of activities targeting arm function, 6 days a week 6-8 weeks. The hypothesis of this study is patients receiving TR in addition to their usual care will have significantly greater recovery of arm function compared to patients receiving usual care alone.

Study participation will last approximately 8 months and includes 4 in-person visits. At these visits, patients will undergo a variety of assessments including tests of arm function and a single MRI scan of the brain. Patients undergoing TR will receive arm motor training, which consists of 36 sessions of assigned exercises, games, and stroke education; these total 70 minutes in length and occur 6 days a week for 6 weeks; TR subjects will also continue usual care. Patients in the usual care group only will not engage in TR but will instead continue all of the therapies recommended by their medical team. At the end of the study, participants in the usual care group will be offered TR.
Frailty is a dynamic condition encompassing physical, psychological, and social domains. While certain factors are associated with overall or specific frailty domains, research on the correlations between physical, psychological, and social frailty is lacking. This study aims to investigate the associations between physical, psychological, and social frailty in European older adults. The study involved 1781 older adults from the Urban Health Centres Europe project. Baseline and 1-year follow-up data were collected on physical, psychological, and social frailty, along with covariates. Linear regression analyzed unidirectional associations, while cross-lagged panel modeling assessed bi-directional associations. Participants' mean age was 79.57 years (SD = 5.54) and over half were female (61.0%). Physical and psychological frailty showed bi-directional association (effect of physical frailty at baseline on psychological frailty at follow-up: β = 0.14, 95%CI 0.09, 0.19; reversed direction: β = 0.05, 95%CI 0.01, 0.09). Higher physical frailty correlated with increased social frailty (β = 0.05, 95%CI 0.01, 0.68), but no association was found between social and psychological frailty. This longitudinal study found a reciprocal relationship between physical and psychological frailty in older adults. A relatively higher level of physical frailty was associated with a higher level of social frailty. There was no association between social and psychological frailty. These findings underscore the multifaceted interplay between various domains of frailty. Public health professionals should recognize the implications of these interconnections while crafting personalized prevention and care strategies. Further research is needed to confirm these findings and investigate underlying mechanisms.
During the Phase I part of the study, participants receive dalotuzumab intravenously (IV) at 5 mg/kg weekly plus open-label erlotinib at 150 mg daily for 4 weeks. After 4 weeks of therapy, participants in Phase I who do not have disease progression and are satisfactorily tolerating study drug can continue to receive study drug.
Affective symptoms, in particular depressive symptoms are prevalent in up to 60% of all patients with schizophrenia. However, it is still uncertain whether depressive symptoms have a prognostic value, having previously been associated with both favorable and poor outcome. In addition, treatment of affective symptoms in patients with schizophrenia is difficult. There is some evidence that atypical antipsychotics such as quetiapine may contribute not only to a reduction in psychotic symptoms but also that these agents may produce an antidepressant effect in schizophrenia and may reduce suicidality. Most of these studies suffer from methodological limitations as the efficacy on affective symptoms has not been the primary target parameter. Concerning the prevalence of affective symptoms in first-episode psychosis knowledge is still poor. This is why we have developed a study design for a pilot-study on 60 patients with first-episode schizophrenia aiming to demonstrate that a treatment with quetiapine over the period of 6 months shows clinical efficacy on affective, particularly depressive symptoms